Abstract: Provided are human polyclonal immunoglobulin products for use in treating or preventing coronavirus disease. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
May 7, 2024
Assignee:
SAB Biotherapeutics, Inc.
Inventors:
Tom Luke, Christoph L. Bausch, Eddie J. Sullivan, Hua Wu, Kristi A. Egland
Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.
Type:
Grant
Filed:
February 1, 2022
Date of Patent:
May 7, 2024
Assignee:
THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter L. Collins, Ursula J. Buchholz, Bo Liang, Shirin Munir
Abstract: This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
March 26, 2024
Assignee:
nference, Inc.
Inventors:
Colin Pawlowski, Venkataramanan Soundararajan, Arjun Puranik, Murali Aravamudan
Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
Type:
Grant
Filed:
April 6, 2021
Date of Patent:
March 19, 2024
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Enrico Malito, Matthew James Bottomley, Andrea Carfi, Sumana Chandramouli, Kate Luisi
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
March 12, 2024
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
Abstract: Formulations of peptide agents, such as antibodies and antigen-binding fragments thereof, that bind dengue viruses, and methods of their use, are provided.
Abstract: Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
January 23, 2024
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
John Fraser Wright, Guang Qu, Bernd Hauck, Katherine A. High
Abstract: Provided herein are methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of the transgene in the eye. Also provided herein are methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.
Abstract: The present invention relates to recombinantly constructed proteins useful for analytical assays, in particular for determining in a biological sample obtained from an individual the presence of antibodies specific for a rhabdovirus. More particular, the present invention relates to a polypeptide comprising an ectodomain of a rhabdovirus glycoprotein and a heterologous multimerization domain linked to said ectodomain. In one example, a fusion protein of the formula x-y-z is provided, wherein x consists of or comprises such an ectodomain being optionally free of a furin cleavage site, y is a linker moiety, and z is a heterologous multimerization domain optionally selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence, and avidin sequence.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
January 2, 2024
Inventors:
David Anstrom, Eric Martin Vaughn, Arun V. Iyer, Michael B. Roof
Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
January 2, 2024
Assignee:
Pfizer Inc.
Inventors:
Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
Abstract: An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.
Abstract: The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
Type:
Grant
Filed:
November 15, 2021
Date of Patent:
December 12, 2023
Assignees:
The University of North Carolina at Chapel Hill, University of Florida Research Foundation, Inc.
Inventors:
Aravind Asokan, Mavis Agbandje-McKenna, Long Ping Victor Tse, Brittney Gurda
Abstract: Provided herein are methods of detecting and measuring disease-associated analytes such as proteins and antibodies in a sweat sample. Also provided are methods of determining and monitoring the disease state or physiological condition of a subject using small sweat samples.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
December 5, 2023
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Inventors:
Benjamin Katchman, Karen Anderson, Jennifer Blain Christen
Abstract: Provided herein are polypeptides, polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses which can be used as vaccines. Also provided are methods for eliciting an immune response against alphavirus infection using the immunogenic composition comprising the alphavirus mutants described herein.
Type:
Grant
Filed:
August 19, 2021
Date of Patent:
December 5, 2023
Assignees:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, University of Tartu
Inventors:
Lisa Fong Poh Ng, Yi Hao Chan, Andres Merits, Age Utt
Abstract: The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene (e.g., a HEK 293T cell) and rAAV virions made by the method.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
December 5, 2023
Inventors:
Huiren Zhao, Grace Ki Jeong Lee, Thomas Wolfe, Cherylene Plewa, Jackie Z. Sheng
Abstract: The present invention relates to a preparation comprising Epstein-Barr virus-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.